Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Bladou F, Mercado A, Levental M, Ghai S, Chang SD, Milot L, Patel C, Kassam Z, Moore C, Kasivisvanathan V, Loblaw A, Kebabdjian M, Earle CC, Pond GR, Haider MA. Klotz L, et al. Among authors: kebabdjian m. JAMA Oncol. 2021 Apr 1;7(4):534-542. doi: 10.1001/jamaoncol.2020.7589. JAMA Oncol. 2021. PMID: 33538782 Free PMC article. Clinical Trial.
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. Klotz LH, et al. Among authors: kebabdjian m. Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007. Epub 2012 Sep 11. Eur Urol. 2013. PMID: 23040208 Clinical Trial.
An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J. Klotz L, et al. Among authors: kebabdjian m. Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4. doi: 10.1038/pcan.2014.24. Epub 2014 Sep 2. Prostate Cancer Prostatic Dis. 2014. PMID: 25179591 Clinical Trial.
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M, Zhang L, Saad F; Canadian Urology Research Consortium. Klotz L, et al. Among authors: kebabdjian m. J Urol. 2018 Aug;200(2):335-343. doi: 10.1016/j.juro.2018.03.010. Epub 2018 Mar 11. J Urol. 2018. PMID: 29534997 Clinical Trial.
Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
Klotz L, Pond G, Loblaw A, Sugar L, Moussa M, Berman D, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin J, Haider M. Klotz L, et al. Among authors: kebabdjian m. Eur Urol. 2020 Mar;77(3):311-317. doi: 10.1016/j.eururo.2019.10.007. Epub 2019 Nov 8. Eur Urol. 2020. PMID: 31708295 Clinical Trial.
A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer.
Kasivisvanathan V, Chan VW, Clement KD, Levis B, Haider M, Agarwal R, Emberton M, Pond GR, Takwoingi Y, Klotz L, Moore CM; VISION study collaborators. Kasivisvanathan V, et al. PLoS One. 2022 Feb 3;17(2):e0263345. doi: 10.1371/journal.pone.0263345. eCollection 2022. PLoS One. 2022. PMID: 35113918 Free PMC article.
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Machado A, Levental M, Ghai S, Chang SD, Patel C, Kassam Z, Loblaw A, Kebabdjian M, Pond G, Haider MA. Klotz L, et al. Among authors: kebabdjian m. Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00204-3. doi: 10.1016/j.euo.2023.09.013. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37838556